London, ON, Canada
Nov 7, 2024
i-RNA Corporation, a proud University of Western Ontario (UWO) spin-off, officially announces its establishment as a biotech company dedicated to advancing RNA-based therapies in April 2024. The company, rooted in Chakrabarti Lab’s groundbreaking research, is focused on developing innovative treatments for diabetic retinopathy (DR), a leading cause of blindness worldwide.
As part of its strategic development, i-RNA Corporation has successfully secured the transfer of key intellectual property package from the University of Western Ontario. This IP covers novel RNA-based technologies, specifically long non-coding RNA (lncRNA) modulators that play a crucial role in gene regulation. With RNA-based therapies rapidly gaining global recognition as one of the most promising and transmotive areas in modern medicine, i-RNA’s innovative technology positions it at the forefront of this movement. The groundbreaking approach to modulating disease-associated genes holds vast potential for addressing unmet medical needs, particularly on diabetic retinopathy and other retinal diseases.
“This marks a significant milestone in our mission to transform the treatment landscape for DR and other serious conditions,” said Ting Ling, CEO of i-RNA Corporation. “The transfer of intellectual property gives us the tools to push forward with our innovative RNA therapies, and we are eager to build on this foundation through strategic partnerships and collaboration.”
As i-RNA Corporation embarks on its journey, the focus remains on leveraging RNA-based therapeutics to address critical healthcare challenges. The company aims to drive significant progress in research and development, while actively seeking both strategic partners and investors to accelerate its growth and bring innovative treatments to market.
About i-RNA
Based in London, Ontario, i-RNA Corporation is an early-stage spin-off company from the University of Western Ontario, that is dedicated to the development of new innovative methods for the treatment and diagnosis of diabetic retinopathy, a leading cause of blindness worldwide. The company is developing proprietary first-in-class lncRNA-based drugs that are potentially longer lasting, more effective, more robust and less expensive than existing treatments for diabetic retinopathy and other ocular diseases.